ARCHIVES

EntreMed Begins Pilot Phase II Trial Of Small Molecule Angiogenesis Inhibitor.

This article is from The Cancer Letter archive.

Vol. 26 No. 46 | December 15, 2000

Download PDF Visit The Full Archive

Related Articles

AACR Journal Publishes a Henschke Letter Without Disclosure of Conflicts.

April 25, 2008

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

July 30, 2004

Univ. of Rochester Leads Trial Of Combination Chemotherapy For Pancreatic Cancer

November 29, 2002

Mason Asks For Better Technology Transfer In Cancer Prevention

October 30, 1992

FDA Committee nixes Combination Guidelines, Okays New NDA Policy

January 21, 1977

Senate Appropriators Plan Hearing On NCI Ouster Of Fisher

June 3, 1994